NEW YORK —
The company said it plans to trim about 1,500 employees and 250 vacant positions, and that the restructuring will yield pretax savings of about $475 million in 2015.
It announced the cuts Monday, the same day it reported second-quarter earnings grew 16 percent to $417.2 million.
‘‘Today’s results demonstrate that we’re clearly on the right path,’’ CEO David Pyott told analysts. ‘‘The actions announced today will only accelerate our trajectory.’’
The drug maker also said that it has raised its forecast for adjusted 2014 earnings to between $5.74 and $5.80 per share. It expects Botox to deliver net sales ranging from $2.2 billion to $2.28 billion.